Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Concentric Analgesics Data Shows Durable Pain Relief and Earlier Opioid Cessation
Details : CA-008 (vocacapsaicin) a water-soluble prodrug of capsaicin, rapidly releases capsaicin at surgical site triggering the activation of the TRPV1 receptor on pain-specific nerves, producing analgesia.
Brand Name : CA-008
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 06, 2024
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vocacapsaicin
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The pilot study showed that vocacapsaicin, administered during surgery at a dose of 24 mg (0.3 mg/mL solution), reduced pain after coughing by 46% compared to the placebo control during the first 96 hours after surgery (p=0.02).
Brand Name : CA-008
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 30, 2022
Lead Product(s) : Vocacapsaicin
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Evolution Research Group
Deal Size : Undisclosed
Deal Type : Agreement
Details : The company has entered into a formal agreement with Evolution Research Group (ERG), a leading postsurgical pain clinical research site network in the U.S., to conduct its registration trials with CA-008 (vocacapsaicin).
Brand Name : CA-008
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 02, 2022
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Evolution Research Group
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : University of Rochester Medical Center
Deal Size : Undisclosed
Deal Type : Collaboration
Details : URMC will participate in the vocacapsaicin Phase 3 clinical trials and develop innovative methods to capture vocacapsaicin’s benefit to patient recovery and rehabilitation.
Brand Name : CA-008
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 02, 2022
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : University of Rochester Medical Center
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $20.0 million
Deal Type : Financing
Details : Concentric intends to use the proceeds from the financing to further fund Phase 3 development activities for vocacapsaicin, its lead therapeutic candidate for postsurgical pain.
Brand Name : CA-008
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 26, 2022
Lead Product(s) : Vocacapsaicin,Ketorolac Trometamol,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $20.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?